Management of myelofibrosis after ruxolitinib failure.
Myelofibrosis
clinical trials
fedratinib
momelotinib
rational combinations
ruxolitinib failure
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
17
4
2020
medline:
28
4
2021
entrez:
17
4
2020
Statut:
ppublish
Résumé
Over the last decade, the Janus kinase1/2 (JAK1/2) inhibitor ruxolitinib has emerged as a cornerstone of myelofibrosis (MF) management. Ruxolitinib improves splenomegaly and symptoms regardless of driver mutation status, and confers a survival advantage in patients with intermediate-2/high risk MF. However, cytopenias remain problematic, and evidence for a robust anti-clonal effect is lacking. Furthermore, the median duration of spleen response to ruxolitinib in clinical trials is approximately 3 years, and ruxolitinib does not appear to affect the risk of leukemic transformation. There is no therapy approved specifically for patients whose disease 'progresses' on ruxolitinib, defining which remains challenging. The recent regulatory approval of the JAK2 inihibitor fedratinib partially fulfills this unmet need, but much remains to be done. Other JAK inhibitors and a plethora of novel agents are being studied in the ruxolitinib 'failure' setting, as well as 'add-on' therapies to ruxolitinib in patients having a 'sub-optimal' response.
Identifiants
pubmed: 32297800
doi: 10.1080/10428194.2020.1749606
pmc: PMC8565616
mid: NIHMS1621231
doi:
Substances chimiques
Janus Kinase Inhibitors
0
Nitriles
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
ruxolitinib
82S8X8XX8H
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1797-1809Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Références
Br J Haematol. 2015 Jul;170(1):29-39
pubmed: 25824940
Haematologica. 2015 Sep;100(9):1139-45
pubmed: 26069290
Drug Metab Dispos. 2014 Oct;42(10):1656-62
pubmed: 25063672
Blood. 2015 Aug 6;126(6):790-7
pubmed: 26124496
Br J Haematol. 2013 May;161(4):508-16
pubmed: 23480528
Blood. 2017 Mar 30;129(13):1823-1830
pubmed: 28188131
Leukemia. 2018 Nov;32(11):2399-2411
pubmed: 29749399
Neurosci Lett. 2017 Mar 6;642:163-167
pubmed: 28109775
Blood. 2014 Mar 27;123(13):2075-83
pubmed: 24470592
Leuk Lymphoma. 2015 Jul;56(7):2092-7
pubmed: 25641433
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Blood. 2013 Aug 22;122(8):1395-8
pubmed: 23838352
J Clin Invest. 2019 Mar 4;129(4):1596-1611
pubmed: 30730307
Leukemia. 2016 Aug;30(8):1701-7
pubmed: 27211272
Nat Struct Mol Biol. 2019 Oct;26(10):870-879
pubmed: 31582847
Lancet Haematol. 2018 Feb;5(2):e73-e81
pubmed: 29275119
N Engl J Med. 2010 Sep 16;363(12):1117-27
pubmed: 20843246
Hemasphere. 2018 Jun 08;2(3):e54
pubmed: 31723778
J Natl Compr Canc Netw. 2016 Dec;14(12):1572-1611
pubmed: 27956542
Drug Metab Dispos. 2017 Jan;45(1):76-85
pubmed: 27803021
Am J Hematol. 2020 Jun;95(6):594-603
pubmed: 32129512
Haematologica. 2016 Sep;101(9):1065-73
pubmed: 27247324
PLoS One. 2013;8(1):e54826
pubmed: 23382981
Blood Adv. 2018 Sep 25;2(18):2378-2388
pubmed: 30242099
J Exp Med. 2016 Aug 22;213(9):1723-40
pubmed: 27481130
Leukemia. 2016 Aug;30(8):1772-5
pubmed: 26975727
Nat Med. 2015 Dec;21(12):1473-80
pubmed: 26569382
J Clin Oncol. 2017 Dec 1;35(34):3844-3850
pubmed: 28930494
Nature. 2012 Sep 6;489(7414):155-9
pubmed: 22820254
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
J Hematol Oncol. 2017 Feb 22;10(1):55
pubmed: 28228106
Blood. 2011 Dec 8;118(24):6392-8
pubmed: 21860020
Cancer Cell. 2018 Jan 8;33(1):29-43.e7
pubmed: 29249691
J Clin Invest. 2017 Apr 3;127(4):1316-1320
pubmed: 28240607
Cancer. 2020 Mar 15;126(6):1243-1252
pubmed: 31860137
Blood. 2017 Dec 28;130(26):2848-2859
pubmed: 29042365
Blood. 2017 Aug 31;130(9):1125-1131
pubmed: 28674026
N Engl J Med. 2015 Sep 3;373(10):908-19
pubmed: 26332545
Curr Hematol Malig Rep. 2018 Jun;13(3):164-172
pubmed: 29796726
Clin Cancer Res. 2019 Apr 1;25(7):2323-2335
pubmed: 30563936
J Hematol Oncol. 2013 Oct 29;6(1):81
pubmed: 24283202
J Hematol Oncol. 2018 Aug 7;11(1):101
pubmed: 30086777
Cell Rep. 2013 Nov 27;5(4):1047-59
pubmed: 24268771
Clin Cancer Res. 2019 Aug 15;25(16):4898-4906
pubmed: 31061068
Cancer Res. 2008 May 1;68(9):3421-8
pubmed: 18451170
Hematol Oncol. 2018 Feb;36(1):285-290
pubmed: 28512865
Leukemia. 2018 May;32(5):1200-1210
pubmed: 29459662
JAMA. 2018 Jun 12;319(22):2299-2307
pubmed: 29800034
Ann Hematol. 2021 Oct 8;:
pubmed: 34622316
Blood. 2014 Jul 3;124(1):151-2
pubmed: 24993879
Leuk Res. 2019 Apr;79:38-44
pubmed: 30849661
Blood. 2018 Nov 29;132(22):2339-2350
pubmed: 30333119
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e463-e468
pubmed: 30115545
Ann Hematol. 2018 Mar;97(3):435-441
pubmed: 29189896
JAMA Oncol. 2018 May 1;4(5):652-659
pubmed: 29522138
Cell. 2007 Mar 23;128(6):1173-86
pubmed: 17382885
Leukemia. 2019 Aug;33(8):1978-1995
pubmed: 30718771
Lancet Haematol. 2017 May;4(5):e225-e236
pubmed: 28336242
Haematologica. 2019 May;104(5):947-954
pubmed: 30442723
Mol Cancer Ther. 2013 May;12(5):577-88
pubmed: 23445613
N Engl J Med. 2019 Apr 25;380(17):1628-1637
pubmed: 31018069
Leukemia. 2017 Sep;31(9):1962-1974
pubmed: 28008177
Leukemia. 2012 Sep;26(9):2039-51
pubmed: 22699452
Lancet Haematol. 2017 Jul;4(7):e317-e324
pubmed: 28602585
Blood. 2012 Aug 9;120(6):1202-9
pubmed: 22718840
JAMA Oncol. 2015 Aug;1(5):643-51
pubmed: 26181658
Leukemia. 2017 Apr;31(4):882-888
pubmed: 27740634